Inno-206
Hematological Neoplasms
Sumitomo Pharma America, Inc.Phase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Hematological Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bortezomib Sumitomo Pharma America, Inc. | Phase 2 | B |
PEGFILGRASTIM Armando Santoro, MD | Phase 2 | B |
Azacitidine Celgene | Phase 1 | CC |
Tcr Transduced T-Cells National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →